Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in Advanced Solid Tumors
NCT04068519Phase 2Completed
- Sponsor
- BeiGene
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in solid tumor (advanced stage), sponsored by BeiGene. Started Dec 2016; status: completed.
02
Drugs
tislelizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04068519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068519.